Back to top
more

Adaptive Biotechnologies (ADPT)

(Delayed Data from NSDQ)

$14.47 USD

14.47
2,053,441

+0.09 (0.63%)

Updated Oct 6, 2025 04:00 PM ET

After-Market: $14.41 -0.06 (-0.41%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

by Zacks Equity Research

Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.

Zacks Equity Research

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Zacks Equity Research

CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU

by Zacks Equity Research

CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.

Zacks Equity Research

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

by Zacks Equity Research

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

Zacks Equity Research

Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update

by Zacks Equity Research

KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.

Zacks Equity Research

FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer

by Zacks Equity Research

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.

Zacks Equity Research

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

by Zacks Equity Research

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

Zacks Equity Research

Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Cardinal Health (CAH) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Zacks Equity Research

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

by Zacks Equity Research

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Zacks Equity Research

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

by Zacks Equity Research

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Zacks Equity Research

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

by Zacks Equity Research

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

Zacks Equity Research

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

by Zacks Equity Research

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice

by Zacks Equity Research

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of +28.76% and +11.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Zacks Equity Research

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

by Zacks Equity Research

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.